1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
James Li
James Li
Articles (565)  | Author's Website |

Stanley Druckenmiller Starts 3 Positions in 3rd Quarter

Guru reports quarterly portfolio

November 15, 2017 | About:

Stanley Druckenmiller (Trades, Portfolio), former partner of George Soros (Trades, Portfolio)’s Quantum Fund, initiated three positions during the third quarter: Citigroup Inc. (NYSE:C), Chubb Ltd. (NYSE:CB) and Celgene Corp. (NASDAQ:CELG).


The Duquesne Capital fund manager invested in 1,095,200 shares of Citigroup for an average price of $68.28 per share. With this transaction, Druckenmiller expanded his portfolio 3.62%.


Citigroup’s profitability ranks 4 out of 10, suggesting modest growth potential. The company’s margins and returns are near a 10-year high yet underperform over 55% of global competitors.



Citigroup has a negative three-year compound annual growth rate (CAGR) of sales, a severe warning sign according to GuruFocus. The company’s revenues in Corporate / Other declined 55% primarily due to the “continued wind-down of legacy non-core assets.” Despite this, overall company revenues increased 2% year over year.



Druckenmiller added 206,600 shares of Chubb for an average price of $144.66 per share. With this transaction, the guru increased his portfolio 1.34%.


Chubb’s profitability rank of 5 suggests the company has satisfactory growth potential. The company said in its third-quarter report that although revenues increased 1% from the prior-year quarter, it still reported a net loss of $70 million due to a $1.893 billion pretax catastrophe loss as a result of the three hurricanes and other natural disasters.



Druckenmiller added 188,100 shares of Celgene for an average price of $135.96 per share. With this transaction, the fund manager increased his portfolio 1.25%.


Celgene’s profitability rank of 9 suggests strong short-term growth potential. The company reported net product sales of $3.283 billion for the quarter, up 11% from the prior-year quarter. The strong increase in product sales contributed to a three-year revenue growth of 22.80%, which outperforms 76% of global biotech companies.


Disclosure: I do not have positions in the stocks mentioned.

About the author:

James Li
I am an editorial assistant and researcher at GuruFocus. I have a Master's in Finance from SMU, and I enjoy writing reports on financial trends and investor portfolios. Follow me on Twitter at @JamesLiGuru!

Visit James Li's Website

Rating: 0.0/5 (0 votes)


Please leave your comment:

Performances of the stocks mentioned by James Li

User Generated Screeners

HOLKLSUQuick Look Group 2018 Late Sta
HOLKLSUEquity Income 2018 Group Late
HOLKLSULucky 20 Value 2018 Group Late
HOLKLSUTop 20 Group 2018 Late Stage S
HOLKLSUMini Group 2018 Late Stage Sec
HOLKLSUTop 20 Group Q3 2018 SHUT Sect
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat